Clin Diabetes. 2024 Aug 27;43(1):6-11. doi: 10.2337/cd24-0001. eCollection 2025 Winter.
ABSTRACT
This article describes a pediatric diabetes center quality improvement initiative to switch youth with type 1 diabetes and diabetic ketoacidosis (DKA) from insulin glargine to longer-duration insulin degludec to determine whether this change would reduce DKA recurrence. Overall, the change in DKA recurrence with degludec was not statistically significant. However, subgroup analysis showed that race/ethnicity and insurance status were significantly associated with change in DKA rates. The association of degludec and decreased rates of repeat DKA in Hispanics and privately insured individuals requires further exploration.
PMID:39829694 | PMC:PMC11739348 | DOI:10.2337/cd24-0001